JP4950044B2 - ボツリヌス毒素の治療的使用 - Google Patents
ボツリヌス毒素の治療的使用 Download PDFInfo
- Publication number
- JP4950044B2 JP4950044B2 JP2007520878A JP2007520878A JP4950044B2 JP 4950044 B2 JP4950044 B2 JP 4950044B2 JP 2007520878 A JP2007520878 A JP 2007520878A JP 2007520878 A JP2007520878 A JP 2007520878A JP 4950044 B2 JP4950044 B2 JP 4950044B2
- Authority
- JP
- Japan
- Prior art keywords
- botulinum toxin
- type
- stones
- botulinum
- stone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
40代後半の女性患者を、中程度の痛みを有する臨床症状に関する直径約1.1cmの胆のうの結石と診断した。ビデオカメラと注入システムの両方を取り付けた内視鏡を胆のう管を介して導入し、そして総投与量200ユニットのボツリヌス毒素A型製剤(例えば、Ipsen Ltd,Slough,UKのDysport(登録商標)、当該製品を製造者の再構成プロトコルに従って使用した。)の注入を、当該胆のうの壁及び管内に実施した。その5〜6日後、症状は緩和された。当該結石の全ての排出が、治療から2週間後の超音波検査により確認された。
50代半ばの男性患者を、痛みを有する臨床症状に関する直径約1.5cmの胆のうの結石と診断した。ビデオカメラと注入システムの両方を取り付けた内視鏡を胆のう管を介して導入し、そして総投与量230ユニットのボツリヌス毒素A型製剤(例えば、Ipsen Ltd,Slough,UKのDysport(登録商標)、当該製品を製造者の再構成プロトコルに従って使用した。)の注入を、当該胆のうの壁及び管内に実施した。体外衝撃波砕石術を計画し、そしてボツリヌス毒素療法の2週間後に実施した。当該結石の排出は容易であり、痛みはなかった。
40代の男性患者を、X線により確認された顎下腺内の長さ約14mm及び直径約9mmの大きな唾液腺の結石と診断した。顎下唾液腺への手段を患者の口からとし、そして総投与量125ユニットのボツリヌス毒素A型製剤(例えば、Ipsen Ltd,Slough,UKのDysport(登録商標)、当該製品を製造者の再構成プロトコルに従って使用した。)の注入を実施した。当該腺の定期的なマッサージを助言し、予期される分泌物の減少を補った。その後まもなく、当該患者は痛みの緩和を経験し、次いで、当該腺の膨張及び炎症は著しく減少した。当該ボツリヌス毒素療法の1週間後、当該患者の結石の経過及び最終的な排出を、超音波又はX線により確認した。
40代後半の女性患者を、疼痛症状に関する約9mmの腎臓の結石と診断した。ビデオカメラと注入システムの両方を取り付けた尿管鏡を尿管を介して導入し、そして総投与量125ユニットのボツリヌス毒素A型製剤(例えば、Ipsen Ltd,Slough,UKのDysport(登録商標)、当該製品を製造者の再構成プロトコルに従って使用した。)の注入を、当該尿管内に実施した。痛み及び出血の減少が見られた。数日後、当該患者の結石は、超音波検査に見られるように自然経路により放出された。
60代後半の男性患者を、外科的手術の決断を正当化するほどの重大な痛みに関する約1.8cmの腎臓の結石と診断した。代案として、総投与量250ユニットのボツリヌス毒素A型製剤(例えば、Ipsen Ltd,Slough,UKのDysport(登録商標)、当該製品を製造者の再構成プロトコルに従って使用した。)の注入を、尿管鏡を用いて当該腎臓及び尿管内に実施した。痛み及び出血の減少が見られた。約1週間後、体外衝撃波砕石術を実施し、そして当該患者の石の断片は自然経路により放出され、患者の尿中にろ過された。
50代半ばの男性患者を、著しい疼痛症状に関する約9mmのすい管の結石と診断した。ビデオカメラと注入システムの両方を取り付けた内視鏡をすい管中に導入し、そして総投与量125ユニットのボツリヌス毒素A型製剤(例えば、Ipsen Ltd,Slough,UKのDysport(登録商標)、当該製品を製造者の再構成プロトコルに従って使用した。)の注入を、当該すい管内に実施した。痛みの減少が見られた。数日後、当該患者の結石は、超音波検査に見られるように自然経路により放出された。
Claims (7)
- 唾液腺結石及びすい臓結石からなる群より選択される自然に形成された結石により遮断された腺、器官又は導管の当該結石の自然排出による治療のための、遮断された腺、器官又は導管に直接注入される、A型、B型、C型、D型、F型又はG型より選択されるボツリヌス毒素を含む薬剤。
- 前記自然に形成された結石が唾液腺結石である、請求項1に記載の薬剤。
- 前記自然に形成された結石がすい臓結石である、請求項1に記載の薬剤。
- 前記ボツリヌス毒素が、ボツリヌス毒素A型、ボツリヌス毒素B型、及びボツリヌス毒素F型からなる群より選択される、請求項1に記載の薬剤。
- 前記ボツリヌス毒素が、ボツリヌス毒素A型である、請求項4に記載の薬剤。
- 前記ボツリヌス毒素が、ボツリヌス毒素複合体である、請求項1に記載の薬剤。
- 前記ボツリヌス毒素が、高純度ボツリヌス神経毒素である、請求項1に記載の薬剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0415490.2 | 2004-07-12 | ||
GB0415490A GB2417419A (en) | 2004-07-12 | 2004-07-12 | Therapeutic use of Botulinum toxin |
PCT/GB2005/002659 WO2006005912A2 (en) | 2004-07-12 | 2005-07-06 | Use of botulinum toxin for the preparation of a medicament for the treatment of lithiasis of salivary gland, gall bladder, kidney, or pancreas |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008505962A JP2008505962A (ja) | 2008-02-28 |
JP2008505962A5 JP2008505962A5 (ja) | 2008-08-21 |
JP4950044B2 true JP4950044B2 (ja) | 2012-06-13 |
Family
ID=32865774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007520878A Expired - Fee Related JP4950044B2 (ja) | 2004-07-12 | 2005-07-06 | ボツリヌス毒素の治療的使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7838009B2 (ja) |
EP (1) | EP1773378B1 (ja) |
JP (1) | JP4950044B2 (ja) |
AR (1) | AR049977A1 (ja) |
AT (1) | ATE380556T1 (ja) |
CA (1) | CA2573441A1 (ja) |
DE (1) | DE602005003836T2 (ja) |
ES (1) | ES2297730T3 (ja) |
GB (1) | GB2417419A (ja) |
WO (1) | WO2006005912A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2420430T3 (es) | 2005-03-03 | 2013-08-23 | Allergan, Inc. | Sistema libre de productos de origen animal y procedimiento de purificación de una toxina botulínica |
FR2902341B1 (fr) * | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
ES2441961T3 (es) * | 2007-02-15 | 2014-02-07 | Allergan, Inc. | Composiciones de toxina botulínica y métodos |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
US7455845B2 (en) * | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
ES2247817T3 (es) * | 1998-07-06 | 2006-03-01 | Nanobac Oy | Metodo para la erradicacion de nanobacterias. |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
-
2004
- 2004-07-12 GB GB0415490A patent/GB2417419A/en not_active Withdrawn
-
2005
- 2005-07-06 CA CA002573441A patent/CA2573441A1/en not_active Abandoned
- 2005-07-06 US US11/632,222 patent/US7838009B2/en not_active Expired - Fee Related
- 2005-07-06 AT AT05757840T patent/ATE380556T1/de not_active IP Right Cessation
- 2005-07-06 WO PCT/GB2005/002659 patent/WO2006005912A2/en active Application Filing
- 2005-07-06 JP JP2007520878A patent/JP4950044B2/ja not_active Expired - Fee Related
- 2005-07-06 EP EP05757840A patent/EP1773378B1/en not_active Not-in-force
- 2005-07-06 ES ES05757840T patent/ES2297730T3/es active Active
- 2005-07-06 DE DE602005003836T patent/DE602005003836T2/de active Active
- 2005-07-12 AR ARP050102875A patent/AR049977A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2573441A1 (en) | 2006-01-19 |
WO2006005912A3 (en) | 2006-04-20 |
EP1773378B1 (en) | 2007-12-12 |
ES2297730T3 (es) | 2008-05-01 |
JP2008505962A (ja) | 2008-02-28 |
GB0415490D0 (en) | 2004-08-11 |
DE602005003836T2 (de) | 2009-01-15 |
WO2006005912A2 (en) | 2006-01-19 |
AR049977A1 (es) | 2006-09-20 |
US7838009B2 (en) | 2010-11-23 |
DE602005003836D1 (de) | 2008-01-24 |
ATE380556T1 (de) | 2007-12-15 |
GB2417419A (en) | 2006-03-01 |
EP1773378A2 (en) | 2007-04-18 |
US20080292661A1 (en) | 2008-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4950044B2 (ja) | ボツリヌス毒素の治療的使用 | |
EP1242110B1 (en) | Composition for treating prostate cancer | |
CA2308842C (en) | Amelioration of peyronie's disease | |
KR20080108996A (ko) | 셀룰라이트 치료용 아교질분해효소 | |
Chang et al. | Extracorporeal shock wave lithotripsy for obstructed proximal ureteral stones | |
WO2007100590A2 (en) | Methods for treating cellulite | |
Albert et al. | Successful outpatient treatment of gallstones with piezoelectric lithotripsy | |
KR20190005149A (ko) | 보툴리눔 독소의 투여를 위한 개선된 방광 주사 패러다임 | |
Olmarker et al. | Micro vascular Effects of Chondroitinase ABC and Chymopapain An In Vivo Experimental Study on Hamsters and Rabbits. | |
Casscells | Aspergillus osteomyelitis of the tibia. A case report. | |
RU2005488C1 (ru) | Средство для лечения болезней соединительной ткани | |
CN108289934A (zh) | 用于伤口愈合的纤溶酶原给药方案 | |
Sedik et al. | Huge carbuncle of the neck with intracranial extension: a case report | |
DICKSON et al. | The use of sulfathiazole in the treatment of subacute and chronic osteomyelitis | |
Paterson | Malignant granuloma of the nose | |
CN108888664A (zh) | 一种治疗结石的中药组合 | |
İLKER et al. | Ureteral extracorporeal shock wave lithotripsy utilizing Dornier MFL 5000 | |
US20150343036A1 (en) | Methods for reducing the occurrence or preventing formation of bladder calculi | |
UA14820U (en) | Method for preventing acute pancreatitis after endoscopic retrograde pancreatocholangiography and endoscopic papillosphincterotomy | |
Нікітін et al. | Urolithiasis: from past to present | |
Nikitin et al. | Urolithiasis: from past to present | |
SU1703111A1 (ru) | Способ лечени коллоидных кист щитовидной железы | |
Huang | Which method is better for simple renal cysts, percutaneous aspiration or laparoscopic unroofing | |
RU2093079C1 (ru) | Способ лимфотропной терапии заболеваний печени и желчевыводящих путей | |
Ze et al. | 282: Evaluation of 24-hour urine risk factors for the patients with renal idiopathic calcium stone disease. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080704 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080704 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120104 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120207 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120308 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150316 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4950044 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |